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Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF) is gaining momentum as a tool for
bacterial identification in the clinical microbiology laboratory. Compared with conventional methods, this technology can more
readily and conveniently identify a wide range of organisms. Here, we report the findings from a multicenter study to evaluate
the Vitek MS v2.0 system (bioMérieux, Inc.) for the identification of aerobic Gram-positive bacteria. A total of 1,146 unique
isolates, representing 13 genera and 42 species, were analyzed, and results were compared to those obtained by nucleic acid
sequence-based identification as the reference method. For 1,063 of 1,146 isolates (92.8%), the Vitek MS provided a single
identification that was accurate to the species level. For an additional 31 isolates (2.7%), multiple possible identifications
were provided, all correct at the genus level. Mixed-genus or single-choice incorrect identifications were provided for 18
isolates (1.6%). Although no identification was obtained for 33 isolates (2.9%), there was no specific bacterial species for
which the Vitek MS consistently failed to provide identification. In a subset of 463 isolates representing commonly en-
countered important pathogens, 95% were accurately identified to the species level and there were no misidentifications.
Also, in all but one instance, the Vitek MS correctly differentiated Streptococcus pneumoniae from other viridans group
streptococci. The findings demonstrate that the Vitek MS system is highly accurate for the identification of Gram-positive
aerobic bacteria in the clinical laboratory setting.
In the clinical microbiology laboratory, bacteria are typicallyidentified using phenotypic and biochemical methods. These
methods are generally reliable but have several drawbacks. In par-
ticular, they can be time-consuming, sometimes taking several
days before a definitive identification can be reached. Further-
more, many are subjectively interpreted, rendering them suscep-
tible to misinterpretation and requiring substantial training and
experience on the part of the technologist to establish and main-
tain competency. In the case of someGram-positive bacteria, such
as the coagulase-negative staphylococci, the viridans group strep-
tococci, and some enterococci, distinguishing one species from
another using these methods can be unreliable or overly compli-
cated (1). Thus, many laboratories do not attempt to distinguish
among them, or do so only selectively.
Matrix-assisted laser desorption–ionization time of flightmass
spectrometry (MALDI-TOF MS) has the potential to address
these drawbacks. Proteomic analysis of bacteria by mass spec-
trometry can be performed as soon as colonies are isolated, often
in primary culture, and the analysis itself takes just a few minutes
(2–6). Thus, on average, routine bacterial identifications can be
obtained more than 30 hours earlier than identification by con-
ventional methods (7). MALDI-TOF MS also provides equal or
superior accuracy compared with conventional phenotypicmeth-
ods (8–10) and does not require subjective interpretation. Finally,
it can readily differentiate bacterial species that have similar phe-
notypic characteristics (11–19).
There are only a few commercially available MALDI-TOF MS
systems used for identification of bacteria. Numerous studies have
described the performance of the two most common, the Bruker
Biotyper and the bioMérieux VitekMSRUO, primarily compared
to phenotypic testing as the referencemethod (3, 4, 6, 8, 9, 13–23).
There are currently no published reports available on the perfor-
mance of the Vitek MS IVD system, with its new method of spec-
tral analysis and updated database (version 2.0). Here, we report
the findings of a large multicenter evaluation of the VitekMS v2.0
system for the identification of Gram-positive aerobic bacteria in
which DNA sequence-based identification served as the reference
method.
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Study sites. The performance of the Vitek MS v2.0 system (bioMérieux,
Inc., Durham, NC) was assessed at five sites within the United States
(Boston, MA; St. Louis, MO; Los Angeles, CA; Lake Success, NY; and
Cleveland,OH). Prior to initiation of the study, operators at each site were
trained in target slide preparation, instrument use, and result review. Each
operator was required to demonstrate proficiency by successfully analyz-
ing a masked panel of organisms consisting of 10 isolates representing
common aerobic and anaerobic Gram-positive and Gram-negative bac-
teria and yeasts. This study was approved by the human subject commit-
tees at the respective sites, when deemed necessary by their internal review
boards.
Bacterial isolates. Fresh isolates obtained in the course of routine
clinical work during the study period were collected and tested at each of
the study sites. Each site was responsible for analyzing a minimum of 10
isolates per species for a predetermined set of frequently encountered
organisms (Enterococcus faecalis, Enterococcus faecium, Staphylococcus au-
reus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus
pneumoniae, and Streptococcus pyogenes) and six isolates per species for a
predetermined set of less frequently encountered organisms (including
Enterococcus avium, Enterococcus casseliflavus, Enterococcus durans, En-
terococcus gallinarum, Gardnerella vaginalis, Listeria monocytogenes, Mi-
crococcus luteus/lylae, Staphylococcus capitis, Staphylococcus haemolyticus,
Staphylococcus hominis subsp. hominis, Staphylococcus lugdunensis, Staph-
ylococcus saprophyticus, Staphylococcus simulans, Staphylococcus warneri,
Streptococcus anginosus, Streptococcus constellatus, Streptococcus dysgalac-
tiae subsp. equisimilis, Streptococcus mitis/Streptococcus oralis, and Strep-
tococcus sanguinis). In the event that a rarer organism, not included in the
list above, was tested, it was included in the study. If a site was unable to
obtain the minimum number of preselected species, additional testing of
frozen isolates obtained from their culture collections or provided by the
study sponsor was permitted. In all cases, cultures were incubated under
standard conditions for a minimum of 18 h at 35 to 37°C in ambient air
or with CO2 enrichment. Each isolate was analyzed on the Vitek MS
system within 72 h of visible growth either from the primary culture or
from a subculture. Subculturing was performed when colonies on the
primary culture plate were insufficiently isolated or for convenience to
allow batching. All subculturing was performed using tryptic soy agar
with 5% sheep blood (Remel, Lenexa, KS). More than 95% of the
isolates were tested after growth on this medium. Of the remaining
isolates, 53 were tested after growth on brucella agar supplemented
with 5% horse blood (Remel, Lenexa, KS), two after growth on choc-
olate agar (Remel, Lenexa, KS), and one after growth on human blood-
Tween bilayer (BD, Franklin Lakes, NJ). Frozen (archived) isolates
were serially subcultured twice on tryptic soy agar with 5% sheep
blood prior to analysis. Duplicate isolates of the same species from the
same patient were not included in the study.
Sample preparation for MALDI-TOF MS analysis. Isolated bacterial
colonies were applied to a single well of a disposable, barcode-labeled
target slide (VitekMS-DS; bioMérieux, Inc.) using a 1.0-l loop, overlaid
with 1.0 l of a saturated solution of alpha-cyano-4-hydroxycinnamic
acid matrix in 50% acetonitrile and 2.5% trifluoroacetic acid (Vitek MS-
CHCA; bioMérieux, Inc.), and air dried. The same bacterial culture was
also used to set up a slide for Gram stain and prepare the organism for
shipment to a centralized laboratory for reference testing.
For instrument calibration, an Escherichia coli reference strain
(ATCC 8739) was transferred to designated wells on the target slide
using the procedure described above. For quality control purposes,
positive and negative controls were analyzed on each day of testing.
The positive control consisted of at least one of four quality control
organisms, including Staphylococcus aureus (ATCC 29213), Klebsiella
oxytoca (ATCC 13182), Pseudomonas aeruginosa (ATCC 10145), and
Enterobacter aerogenes (ATCC 13048). The negative control was ma-
trix alone.
Organism identification using the Vitek MS v2.0 system. The Vitek
MS v2.0 system includes an OEM (original equipment manufacturer)-
labeled Shimadzu AXIMA Assurance mass spectrometer linked to a
reference database, referred to as Knowledge Base. During target in-
terrogation, mass spectra within a range of 2,000 to 20,000 Da are
recorded in linear positive mode at a laser frequency of 50 Hz. For each
interrogation, laser shots at different positions within the target well
produce up to 100 mass profiles that are summed into a single, raw
mass spectrum. The spectrum is then processed by baseline correction,
denoising, and peak detection to identify well-defined peaks. The list
of these significant peaks is subjected to a proprietary process called
“mass binning” (see the supplemental material). The processed
(binned) data are used to query Knowledge Base to determine the
unknown’s taxonomic identity. These results are then provided in the
form of a single species-level (and sometimes subspecies-level) iden-
tification, a split (low discrimination) identification with up to four
species-level alternatives displayed, or no identification. For the pres-
ent study, when a report of “no identification” was provided, or when
analysis of an isolate yielded absent or poor-quality spectra, the organ-
ism was reanalyzed a single time on a new target slide. Isolates yielding
split identifications were not reanalyzed. Additionally, isolates that
yielded a reference identification that is not included in the database
were excluded from analysis.
Reference method for bacterial identification. All study isolates were
sent to a centralized laboratory (MIDI Labs, Inc., Newark, DE) for nucleic
acid sequence-based identification. Sequencing of a 527-bp region within
the 16S rRNA gene was performed using universal 16S primers at posi-
tions 0005F and 0531R (MicroSeq system; Applied Biosystems, Carlsbad,
CA). The resulting sequence was run through the MicroSeq, GenBank,
and BiBi databases to determine the identity. In the event of a discrepancy
or low-discrimination result, or when no match was obtained using this
method, supplemental sequencing of a different gene target (sodA or
rpoB) and/or phenotypic testing was performed by bioMérieux, Inc.
(Durham, NC).
Analysis. The Vitek MS result was considered accurate to the species
level if a single identification was given and it matched that obtained by
the reference method. The Vitek MS result was considered correct to
the genus level if multiple alternative identifications, all from the same
genus, were reported and this matched the genus obtained by the
reference method. The Vitek MS result was considered incorrect if a
single identification was given that did not match (at some taxonomic
level) the result obtained with the reference method, when multiple
identifications of different genera were reported, or when multiple
identifications of the same genera were reported but did match the
genus of the reference method.
RESULTS
Overall results. A total of 1,146 unique, aerobic, Gram-positive
isolates was analyzed, representing 16 genera and 42 species. As
shown in Table 1, for 1,063 isolates (92.8%), the Vitek MS pro-
vided a single identification that matched at the species level the
identification obtained by the referencemethod. An additional 31
isolates (2.7%) were correctly identified to the genus level, mean-
ing that the Vitek MS result included a split identification with
multiple alternative species all from the same genus, and the genus
in all casesmatched that obtained by the referencemethod (Tables
1 and 2). For all but one of these isolates, the correct species was
listed among the alternate identifications provided (Table 2). A
total of 18 isolates were not accurately identified (1.6%) (Tables 1
and 3). This included seven isolates for which a single identifica-
tion was provided that was accurate to the genus level but not the
species level, two isolates for which multiple identifications were
provided, all of which were incorrect to the genus level, and nine
isolates wheremultiple different genera were reported. In the later
Rychert et al.
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No. (%) with Vitek MS result
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Common pathogens 463 442 (95) 4 (1) 17 (4)
Enterococcus faecalis 62/6/0 66 (97) 2 (3)
Enterococcus faecium 41/16/0 57 (100)
Staphylococcus aureus 59/2/0 60 (98) 1 (2)
Staphylococcus lugdunensis 25/8/0 33 (100)
Staphylococcus saprophyticus 26/9/0 32 (91) 3 (9)
Streptococcus pneumoniae 45/6/0 49 (96) 2 (4)
Streptococcus pyogenes 45/10/0 53 (96) 2 (4)
Streptococcus agalactiae 53/5/0 58 (100)
Listeria monocytogenes 12/33/0 34 (76) 4 (9) 7 (15)
Other enterococci 134 130 (97) 1 (1) 1 (1) 2 (1)
Enterococcus avium 16/15/2 30 (91) 1 (3) 2 (6)
Enterococcus casseliflavus 13/22/2 37 (100)
Enterococcus durans 2/7/21 29 (97) 1 (3)
Enterococcus gallinarum 10/19/5 34 (100)
Other coagulase-negative Staphylococci 249 240 (96) 8 (3) 1 (1)
Staphylococcus capitis 26/8/0 32 (94) 2 (6)
Staphylococcus cohnii 2/0/0 2 (100)
Staphylococcus epidermidis 78/10/0 86 (98) 2 (2)
Staphylococcus haemolyticus 23/15/0 38 (100)
Staphylococcus hominis 17/3/1 21 (100)
Staphylococcus schleiferi 1/1/0 2 (100)
Staphylococcus simulans 11/14/6 31 (100)
Staphylococcus warneri 14/7/12 28 (85) 4 (12) 1 (3)
Other streptococci 218 178 (82) 25 (11) 4 (2) 11 (5)
Streptococcus anginosus 18/22/7 45 (96) 2 (4)
Streptococcus constellatus 7/19/4 26 (86) 2 (7) 2 (7)
Streptococcus dysgalactiae 18/25/4 24 (51) 20 (43) 3 (6)
Streptococcus gallolyticus 3/0/0 3 (100)
Streptococcus infantarius 5/0/0 4 (100)
Streptococcus intermedius 6/7/0 11 (85) 2 (15)
Streptococcus mitis/oralis 29/7/0 32 (86) 1 (3) 1 (3) 3 (8)
Streptococcus mutans 1/0/0 1 (100)
Streptococcus salivarius 2/0/0 2 (100)
Streptococcus sanguinis 9/8/17 31 (91) 3 (9)
Other genera 81 73 (90) 1 (1) 5 (6) 2 (2)
Abiotrophia defective 2/0/0 2 (100)
Aerococcus viridans 6/0/0 6 (100)
Corynebacterium jeikeium 1/0/0 1 (100)
Gardnerella vaginalis 11/0/16 24 (89) 3 (11)
Gemella haemolysans 3/0/0 3 (100)
Granulicatella adiacens 1/0/0 1 (100)
Lactococcus garvieae 1/0/0 1 (100)
Lactococcus lactis 0/1/0 1 (100)
Leuconostoc mesenteroides 1/0/0 1 (100)
Micrococcus luteus/lylae 16/8/11 33 (94) 1 (3) 1 (3)
Rothia mucilaginosa 3/0/0 1 (33) 1 (33) 1 (33)
Total 1,146 1,063 (92.8) 31 (2.7) 18 (1.6) 33 (2.9)
a Fresh isolates were those obtained during the normal clinical workflow; archived isolates were obtained from frozen stocks at one of the trial sites; sponsor isolates were obtained
from the sponsor’s frozen stocks. Sponsor-derived isolates were not used in the development of Knowledge Base.
b The result was a single identification that matched the reference method to the species level.
c The result was multiple possible identifications, all within the same genus, which matched (at the genus level) the identification obtained by the reference method.
d The result was either a single identification that did not match the identification obtained by the reference method or multiple possible identifications that included more than one
genus.
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cases, the correct species-level identification was included among
the alternatives. Finally, no identification was obtained for 33 iso-
lates, all of which were represented in the database (2.9%) (Table
1). There was no specific bacterial species for which the Vitek MS
consistently failed.
Commonly encountered important pathogens. Given the
breadth of species analyzed in this study, some of which are rarely
encountered in the clinical microbiology laboratory, we consid-
ered the performance of theVitekMS system for the identification
of a subset of commonly encountered and clinically important
Gram-positive bacteria (Table 1). This set of organisms was cho-
sen prior to data analysis on the basis of being pathogenic and
commonly isolated from clinical specimens. Among the 463 iso-
lates included in this group, 95% were accurately identified. The
level of accuracy was similar to that for all isolates combined (P
0.0557, Fisher exact test). Although 17 isolates (4%) within this
subset were not identified, there were no organisms within this
subgroup that were misidentified. Listeria monocytogenes was the
only organism within this group that was correctly identified to
the species level less than 90%of the time (Table 1). Seven of the 45
L. monocytogenes isolates (15%) were not identified, and an addi-
tional four (9%) were correctly identified to the genus but not the
species level (listed in Table 2).
Other enterococci, staphylococci, and streptococci. Among
the Gram-positive bacteria, the enterococci, staphylococci, and
streptococci are the most commonly encountered in the clinical
laboratory. Aside from the organisms included above, identifica-
tion of these bacteria to the species level may not be feasible using
conventional methods due to the poor specificity and technical
challenges of these methods. With this in mind, we determined
the performance of the VitekMS in accurately identifying these
groups of organisms (Table 1). Of the 134 enterococci, 130
(97%) were correctly identified to the species level. Similarly,
96% of the coagulase-negative staphylococci were correctly
identified to the species level (240 of 249). The accuracy was
lower for the streptococci, with 82% being identified to the
species level (178 of 218). In particular, only 51% of the S.
dysgalactiae isolates were correctly identified to the species
level (24 of 47). The remaining were either not identified or
correctly identified only to the genus level. Importantly, the
Vitek MS correctly distinguished S. pneumoniae from other S.
mitis group streptococci in all but one case. In this case, the
reference method identified an isolate as S. mitis, but the Vitek
MS reported a split identification between S. mitis/oralis and S.
pneumoniae. These data indicate that the Vitek MS can readily
provide species-level identifications for this challenging group
of organisms.
Other genera. The remaining isolates included in the study
represent an additional 10 genera. As shown in Table 1, the ma-
jority of these isolates were correctly identified to either the species
level (90%) or the genus level (1%). Six percent of the isolates in
this groupweremisidentified, including threeG. vaginalis, oneM.
luteus/lylae, and oneRothiamucilaginosa isolate. No identification
TABLE 2 Split identifications reported by the Vitek MS v2.0 system that were accurate to the genus level
Reference identification
No. of
isolates Vitek MS identification
Listeria monocytogenes 3 L. ivanovii, L. monocytogenes
Listeria monocytogenes 1 L. ivanovii, L. monocytogenes, L. welshimeri
Enterococcus avium 1 E. raffinosus, E. avium
Streptococcus constellatus 2 S. anginosus, S. constellatus
Streptococcus dysgalactiae subsp. equisimilis 1 S. equi subsp. zooepidemicus, S. equi subsp. equi
Streptococcus dysgalactiae subsp. equisimilis 19 S. pyogenes, S. dysgalactiae subsp. equisimilis, S. dysgalactiae subsp.
dysgalactiae
Streptococcus intermedius 2 S. constellatus, S. intermedius
Streptococcus mitis 1 S. mitis/oralis, S. pneumoniae
Rothia mucilaginosa 1 R. dentocariosa, R. mucilaginosa
Total 31
TABLE 3 Inaccurate results reported by the Vitek MS v2.0 system
Reference result
No. of
isolates Vitek MS results
Single choice, incorrect to
species
7
Enterococcus durans 1 E. faecium
Staphylococcus
epidermidis




Staphylococcus warneri 1 S. pasteuri
Streptococcus sanguinis 1 S. anginosus




Staphylococcus capitis 1 Corynebacterium coyleae,
Riemerella anatipestifer





Gardnerella vaginalis 3 Bifidobacterium spp., G. vaginalis
Micrococcus lylae 1 M. luteus/lylae, Kocuria rosea
Rothia mucilaginosa 1 Alcaligenes faecalis subsp. faecalis,
R. mucilaginosa
Staphylococcus warneri 3 Prevotella buccalis, S. warneri
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was obtained for 2% of these isolates, including one isolate each of
Leuconostoc mesenteroides andM. luteus/lylae.
DISCUSSION
The purpose of this study was to evaluate the new Vitek MS v2.0
MALDI-TOF mass spectrometry system for the identification of
Gram-positive aerobic bacteria in the clinical laboratory setting.
Compared to the referencemethod, theVitekMS systemprovided
an accurate, species-level identification for more than 92% of the
isolates tested. This level of accuracy is similar to that obtained
using modern biochemical testing platforms (24–28) and other
MALDI-TOF MS systems (4, 6, 8, 12, 21, 23, 29, 30–33). The
advantage of this and other MALDI-TOF MS systems over con-
ventional methods is the potential improvement in turnaround
time and reduction in reagent and labor costs (5, 7, 23, 34). This is
especially true for the less common species of Enterococcus, Staph-
ylococcus, and Streptococcus, which can be difficult to identify at
the species level using conventional methods. Given the similar
level of accuracy among the commercially available MALDI-TOF
MS systems, factors including cost and ease of use will likely influ-
ence the choice of system.
Among themajor commercial MALDI-TOF platforms, the in-
strument, sample preparation, and basic approach to signal acqui-
sition are similar, but the approach to database building and anal-
ysis differs significantly (35). One approach uses a database of
reference mass spectra and a pattern matching algorithm (36). In
this approach, a “mass fingerprint” or peak list with mass-to-
charge values and intensities is generated from an unknown sam-
ple. The mass fingerprint is then compared to a database of refer-
ence mass fingerprints, the mass signals and signal intensity (peak
height) are compared, and the closest matches are identified (35–
37). In contrast, theVitekMS v2.0 uses a “binmatrix” approach to
determine the identity of an unknown organism in comparison to
the reference database (see the supplemental material). This anal-
ysis assigns added weight to species-specific peaks (35), a method
that has been shown to aid in differentiating between very similar
mass spectra derived from closely related species or subspecies
(36). Additional studies are required to determine whether this
difference in spectral analysis leads to improvements in the iden-
tification of bacterial species encountered in the clinical microbi-
ology laboratory.
The Vitek MS v2.0 was able to reliably distinguish between S.
pneumoniae and other S.mitis group species. This appears to be an
advantage of this system in comparison to otherMALDI-TOFMS
systems, which have been reported to misidentify S. mitis group
species (especially S. mitis, S. oralis, and S. pseudopneumoniae) as
S. pneumoniae (2, 8, 21, 23, 38–42). It was previously suggested
that this difficulty may stem from the extremely close relationship
of these species (35). However, it has been demonstrated that the
mass spectra of these organisms do contain characteristic peaks
that clearly distinguish them (43), and in a head-to-head compar-
ison, an earlier version of the Vitek MS system was better able to
discriminate between these organisms than another commercial
MALDI-TOFMS platform (6). Follow up studies are necessary to
corroborate these findings.
This study has several strengths. First, it was a largemulticenter
investigation with good geographic representation using primar-
ily freshly obtained clinical isolates. Second, the study relied upon
nucleic acid sequence-based identification as the reference
method, which is especially unusual for a study of this size, due to
the cost associated with sequencing. Finally, very strict rules were
applied when isolates were tested. In particular, a single deposit
rather than multiple deposits of each isolate was spotted on the
target plate, and protein extraction was not performed. This is a
more stringent approach than has been adopted in other studies
(6, 11, 44). Further, repeated testing was not allowed when split
identifications were obtained. In this regard, the study findings
mayunderestimate the system’s true capabilities, as it is possible to
obtain a single, species-level identification by repeating the anal-
ysis after initially obtaining multiple identifications. Although the
breadth of organisms tested in this study was extensive, one limi-
tation of the study was that there were several species for which
only a small number of isolates were analyzed, and for some of
these it was necessary to supplement the freshly collected isolates
with archived isolates.
In summary, the Vitek MS v2.0 is an accurate and user-
friendly system for identifying Gram-positive aerobic bacteria
in the clinical laboratory. For some clinical microbiology lab-
oratories, adoption of this technology is likely to improve ser-
vice by providing species-level identification for the coagulase-
negative staphylococci and the less common enterococci and
streptococci. It should be noted, however, that this technology
does not supersede the expertise of a trained microbiologist;
Gram staining and colony morphology are still a valuable part
of bacterial identification and can be used to identify errors
that may be overlooked by relying solely on the identification
result provided by the Vitek MS.
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